213 related articles for article (PubMed ID: 32555371)
61. Long-term outcomes of HLA-haploidentical stem cell transplantation based on an FBCA conditioning regimen compared with those of HLA-identical sibling stem cell transplantation for haematologic malignancies.
Long H; Lu ZG; Song CY; Huang YX; Xu JH; Xu JX; Deng L; Tu SF; He YZ; Lin X; Guo KY; Wu BY
Bone Marrow Transplant; 2016 Nov; 51(11):1470-1475. PubMed ID: 27322852
[TBL] [Abstract][Full Text] [Related]
62. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
63. [Unrelated umbilical cord blood transplantation with TBI/Ara-c/CY non-ATG conditioning regimen for adults with hematologic malignancies].
Sun ZM; Liu HL; Geng LQ; Zhou CY; Wang XB; Ding KY; Tong J; Zhu WB; Liu X; Wang ZY
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(24):1660-4. PubMed ID: 22944153
[TBL] [Abstract][Full Text] [Related]
64. Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study.
Chang YJ; Wu DP; Lai YR; Liu QF; Sun YQ; Hu J; Hu Y; Zhou JF; Li J; Wang SQ; Li W; Du X; Lin DJ; Ren HY; Chen FP; Li YH; Zhang X; Huang H; Song YP; Jiang M; Hu JD; Liang YM; Wang JB; Xiao Y; Huang XJ
J Clin Oncol; 2020 Oct; 38(29):3367-3376. PubMed ID: 32650683
[TBL] [Abstract][Full Text] [Related]
65. Reduced platelet transfusions and earlier platelet engraftment using alemtuzumab-based conditioning regimen in allogeneic stem cell transplantation.
Neumann T; Schneidewind L; Thiele T; Schulze M; Klenner AF; Busemann C; Pink D; Greinacher A; Dölken G; Krüger WH
J Cancer Res Clin Oncol; 2016 May; 142(5):1091-7. PubMed ID: 26779644
[TBL] [Abstract][Full Text] [Related]
66. Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants.
Wang H; Liu H; Zhou JY; Zhang TT; Jin S; Zhang X; Chen SN; Li WY; Xu Y; Miao M; Wu DP
Sci Rep; 2017 Mar; 7():43488. PubMed ID: 28262717
[TBL] [Abstract][Full Text] [Related]
67. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG).
Tang F; Xu Y; Chen H; Xu L; Zhang X; Wang Y; Liu Q; Wu D; Huang X
Sci China Life Sci; 2020 Apr; 63(4):571-581. PubMed ID: 31420852
[TBL] [Abstract][Full Text] [Related]
68. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ
Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691
[TBL] [Abstract][Full Text] [Related]
69. Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner MA; Kennedy VE; Tamaresis JS; Lavori PW; Arai S; Johnston LJ; Meyer EH; Miklos DB; Muffly LS; Negrin RS; Rezvani AR; Shizuru JA; Weng WK; Hoppe RT; Strober S; Lowsky R
Blood Adv; 2019 Aug; 3(16):2454-2464. PubMed ID: 31427277
[TBL] [Abstract][Full Text] [Related]
70. Non-fucosylated CB CD34
Robinson SN; Thomas MW; Simmons PJ; Lu J; Yang H; Javni JA; Shpall EJ; Zweidler-Mckay PA
Cytotherapy; 2017 Feb; 19(2):285-292. PubMed ID: 27919572
[TBL] [Abstract][Full Text] [Related]
71. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
72. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
73. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin.
Lamparelli T; van Lint MT; Gualandi F; Raiola AM; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Bregante S; Berisso G; Dominietto A; Di Grazia C; Bruno B; Sessarego M; Casarino L; Verdiani S; Bacigalupo A
Bone Marrow Transplant; 2000 Dec; 26(12):1305-11. PubMed ID: 11223970
[TBL] [Abstract][Full Text] [Related]
74. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
[TBL] [Abstract][Full Text] [Related]
75. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
Chang YJ; Luznik L; Fuchs EJ; Huang XJ
J Hematol Oncol; 2016 Apr; 9():35. PubMed ID: 27071449
[TBL] [Abstract][Full Text] [Related]
76. Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.
Lee SE; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW
Am J Hematol; 2018 Nov; 93(11):1368-1375. PubMed ID: 30117176
[TBL] [Abstract][Full Text] [Related]
77. New Strategy of Acute Graft-vs-Host Disease: Investigation of a Reduced Dose of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation.
Sun Y; Wei C; Cao C; Tan X; Zeng H; Luo Y; Chen L
Transplant Proc; 2019 Apr; 51(3):890-895. PubMed ID: 30979481
[TBL] [Abstract][Full Text] [Related]
78. A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation.
Lee MW; Yeon SH; Seo WH; Ryu H; Lee HJ; Yun HJ; Jo DY; Song IC
Medicine (Baltimore); 2020 Aug; 99(34):e21571. PubMed ID: 32846764
[TBL] [Abstract][Full Text] [Related]
79. Haplo-identical transplantation for acquired severe aplastic anaemia in a multicentre prospective study.
Xu LP; Wang SQ; Wu DP; Wang JM; Gao SJ; Jiang M; Wang CB; Zhang X; Liu QF; Xia LH; Wang X; Huang XJ
Br J Haematol; 2016 Oct; 175(2):265-274. PubMed ID: 27352174
[TBL] [Abstract][Full Text] [Related]
80. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
Wall DA; Carter SL; Kernan NA; Kapoor N; Kamani NR; Brochstein JA; Frangoul H; Goyal RK; Horan JT; Pietryga D; Wagner JE; Kurtzberg J;
Biol Blood Marrow Transplant; 2005 Aug; 11(8):637-46. PubMed ID: 16041314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
